We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
Aptamers-Based Anti-monkeypox Drug Discovery Solutions
Developing effective strategies to combat the virus is essential given the global rise of monkeypox infections that cause skin and systemic disorders, and in some cases, deaths. Since Creative Biolabs has been operating in the life science industry for more than ten years, we are dedicated to offering one-stop aptamers-based anti-monkeypox drug discovery solutions for the discovery of trustworthy monkeypox products and medications associated with monkeypox.
Aptamers are single-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) molecules, which have the ability to adopt complex tertiary structures that allow non-covalent interactions with other molecules. In the viral studies, DNA or RNA was found to have the potential to act as ligands with the ability to bind to target viral proteins and regulate their activity. Due to the lack of toxicity and immunogenicity, aptamers are considered to be well suited for therapeutic applications. The study of viruses provides us a new direction of thinking for the therapeutic treatment of diseases caused by monkeypox and other viruses through certain modifications on aptamers.
Advances in nucleotide synthesis methods have made oligonucleotides easy to produce. PCR techniques have enabled rapid amplification of these molecules. Under the iteration of these two techniques, functional nucleic acids are selected in vitro to obtain the corresponding aptamers. This process is termed Systematic Evolution of Ligands by EXponential enrichment (SELEX). The workflow of SELEX by Creative Biolabs is as follows. First, single-stranded target RNA or DNA molecules are prepared by the in vitro transcription of double-stranded DNA templates or by the strand separation of double-stranded PCR products, which in the length of 20-100 residues with flanked constant sequence for enzymatic manipulation. The target protein is incubated with 1013-1015 randomized DNA or RNA oligonucleotides. After the incubation, the non-binding sequences are removed, while the bound sequences are amplified for the next circle. After 8–12 times of iterative procedure, a large number of oligonucleotide copies with high affinity for the target protein are identified by sequencing, and the individual aptamers are verified by subsequent interaction tests.
Fig.1 The workflow of SELEX.
Aptamers-based Anti-Monkeypox Drug Discovery Solutions at Creative Biolabs
Aptamers have a wide range of applications in viral infections, which can be used for diagnostic purpose, for monitoring protein-nucleic acids and protein-protein interactions, or for the treatment and prevention of viral infections. A virus's lifecycle involves attachment, entry, replication, assembly, and release. Aptamers can be the antiviral therapy targeting each step of the viral lifecycle. Creative Biolabs provides comprehensive aptamers-based anti-monkeypox drug discovery solutions, that play a critical role in research from mechanism to clinical translational application.
DNA Aptamer-based Anti-Monkeypox Drug Discovery Solutions
Monkeypox is a DNA poxvirus. The most effective therapeutic solutions provided by Creative Biolabs are blocking the viral entry into the cells and inhibiting the enzyme activity related to replication. First, aptamers can target the host cell receptors or monkeypox structural proteins to block the viral entry into the host cells. Second, inhibiting the viral polymerases, helicases, and proteases by aptamers can effectively inhibit monkeypox replication. In addition, small interfering RNA (siRNA) delivery of therapeutic molecules to cells infected with viruses reduces the transcriptional process and has less side effects.
RNA Aptamer-based Anti-Monkeypox Drug Discovery Solutions
For certain other RNA viruses, effective aptamer therapeutic strategies at Creative Biolabs include preventing the reverse transcription process by targeting the retroviral reverse transcriptase, preventing the viral mRNA generation by targeting transcriptional factors involved in the viral genome, or preventing the viral genome from being integrated into the host genome by targeting viral integrases.
With cutting-edge high-throughput screening, artificial intelligence, and in vitro and in vivo platforms, Creative Biolabs is dedicated to providing a comprehensive spectrum of monkeypox products and customized solutions for aptamers-based anti-monkeypox drug discovery. To find out more information, please do not hesitate to contact us.